{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.8","value":"5.6"},{"groupId":"OG001","spread":"140","value":"197"},{"groupId":"OG002","spread":"52.7","value":"66.9"},{"groupId":"OG003","spread":"154","value":"237"},{"groupId":"OG004","spread":"35.5","value":"37.0"},{"groupId":"OG005","spread":"118","value":"180"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"40"}],"units":"Participants"}],"description":"Blood samples were collected during the Randomization Phase. Most participants had 6 samples taken over 3 cycles of treatment (sparse sampling - 2 samples taken per cycle, one at predose and one at 2 to 8 hours postdose). Plasma concentrations of lenvatinib were measured and concentration data were summarized. The summary statistics at time points with one or more below the limit of quantitation (BLQ) values were calculated by assigning zero for each BLQ value.","dispersionType":"Standard Deviation","groups":[{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG000","title":"Cycle 1, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG001","title":"Cycle 1, Day 1 (2-8 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG002","title":"Cycle 2, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG003","title":"Cycle 2, Day 1 (2-8 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG004","title":"Cycle 3, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG005","title":"Cycle 3, Day 1 (2-8 Hours)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who have received at least one dose of study drug (lenvatinib or everolimus) and have evaluable concentration data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)","title":"Summary of Plasma Concentrations of Lenvatinib for Sparse Pharmacokinetic (PK) Sampling for Phase 1b and Phase 2","type":"SECONDARY","unitOfMeasure":"ng/mL"}